Toll-like receptor ligands energize peptide vaccines through multiple paths

Cancer Research

Volumn 67, Issue 17, 2007, Pages 7945-7947

  Celis, Esteban ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2 INHIBITOR; GEMCITABINE; MONOCLONAL ANTIBODY; OKT 4; PEPTIDE VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; DISEASE MODEL; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS; VACCINES, SUBUNIT;

EID: 34548569047     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1652     Document Type: Review

References (20)

1. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989;342:561-4.
2. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 2002;77:339-49.
3. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002;1589:1-13.
4. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49-55.
5. + T cells. Immunol Rev 2006;211:81-92.
6. Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood 2002;100:2537-45.
7. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000;165:539-47.
8. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-34.
9. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis 2004;20:33-42.
10. Williams MA, Bevan MJ. Effector and Memory CTL Differentiation. Annu Rev Immunol 2007;25:171-92.
11. + T lymphocytes. Nature 2003;421:852-6.
12. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
13. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-15.
14. + regulatory T cell function. Science 2005;309:1380-4.
15. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007;25:419-41.
16. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425.
17. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/ c mice suppresses immune reactivity. Blood 2003;102:2138-45.
18. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007;30:251-60.
19. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931-9.
20. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.